Provided by Tiger Trade Technology Pte. Ltd.

Ultragenyx Pharmaceutical

26.53
+0.72002.79%
Post-market: 14.39-12.1400-45.76%18:54 EDT
Volume:7.02M
Turnover:136.78M
Market Cap:2.61B
PE:-4.55
High:26.80
Open:25.96
Low:25.57
Close:25.81
52wk High:39.89
52wk Low:18.29
Shares:98.32M
Float Shares:80.72M
Volume Ratio:4.27
T/O Rate:8.70%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-5.8279
EPS(LYR):-5.8316
ROE:-608.47%
ROA:-24.22%
PB:-8.96
PE(LYR):-4.55

Loading ...

Ultragenyx Pharmaceutical Inc: Remain on Path to Profitability in 2027

THOMSON REUTERS
·
May 06

Ultragenyx CFO Howard Horn disposes 4,683 shares worth $116,607.70

Reuters
·
May 05

Press Release: WisdomTree Announces First Quarter 2026 Results

Dow Jones
·
May 01

Northwest Bio appoints Annalisa Jenkins as strategic adviser

Reuters
·
May 01

Ultragenyx Pharma Is Maintained at Overweight by Barclays

Dow Jones
·
Apr 29

Ultragenyx to Host Conference Call for First Quarter 2026 Financial Results and Corporate Update

GlobeNewswire
·
Apr 29

Ultragenyx price target lowered to $43 from $44 at Barclays

TIPRANKS
·
Apr 29

Analysts Offer Insights on Healthcare Companies: CareDx (CDNA) and Ultragenyx Pharmaceutical (RARE)

TIPRANKS
·
Apr 29

Ultragenyx grants 36,447 inducement RSUs to 12 new hires

Reuters
·
Apr 25

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
Apr 25

Analysts Offer Insights on Healthcare Companies: Amgen (AMGN), Medpace Holdings (MEDP) and Ultragenyx Pharmaceutical (RARE)

TIPRANKS
·
Apr 24

Wedbush Lifts Price Target on Ultragenyx Pharmaceutical to $27 From $25, Keeps Neutral Rating

MT Newswires Live
·
Apr 21

Ultragenyx Pharma Is Maintained at Overweight by Morgan Stanley

Dow Jones
·
Apr 17

Ultragenyx price target raised to $67 from $50 at Morgan Stanley

TIPRANKS
·
Apr 16

BROAD ARROW AUCTIONS TO OFFER EXTREMELY RARE GORDON MURRAY AUTOMOTIVE T.50 VIA LIVE AUCTION DURING THE CALIFORNIA MILLE

GlobeNewswire
·
Apr 11

RBC Capital Reaffirms Their Buy Rating on Ultragenyx Pharmaceutical (RARE)

TIPRANKS
·
Apr 09

Ultragenyx says FDA accepts UX111 gene therapy BLA resubmission, sets Sept. 19 PDUFA date

Reuters
·
Apr 02

Ultragenyx Pharmaceutical Inc - FDA Sets Pdufa Action Date for Ux111 on September 19, 2026

THOMSON REUTERS
·
Apr 02

Ultragenyx Announces U.S. FDA Acceptance of Bla Resubmission for Ux111 Aav Gene Therapy to Treat Sanfilippo Syndrome Type a (Mps Iiia)

THOMSON REUTERS
·
Apr 02

Ultragenyx Pharmaceutical Inc - Ux111 to Be Manufactured in U.S. at Andelyn Biosciences and Ultragenyx Facility IF Approved

THOMSON REUTERS
·
Apr 02